CTSO vs. DCTH, TLSI, ARAY, DRTS, CLPT, TELA, QIPT, BWAY, SSKN, and KRMD
Should you be buying Cytosorbents stock or one of its competitors? The main competitors of Cytosorbents include Delcath Systems (DCTH), TriSalus Life Sciences (TLSI), Accuray (ARAY), Alpha Tau Medical (DRTS), ClearPoint Neuro (CLPT), TELA Bio (TELA), Quipt Home Medical (QIPT), BrainsWay (BWAY), STRATA Skin Sciences (SSKN), and KORU Medical Systems (KRMD). These companies are all part of the "surgical & medical instruments" industry.
Delcath Systems (NASDAQ:DCTH) and Cytosorbents (NASDAQ:CTSO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, community ranking, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.
In the previous week, Delcath Systems had 1 more articles in the media than Cytosorbents. MarketBeat recorded 2 mentions for Delcath Systems and 1 mentions for Cytosorbents. Cytosorbents' average media sentiment score of 0.92 beat Delcath Systems' score of 0.00 indicating that Delcath Systems is being referred to more favorably in the media.
Cytosorbents received 413 more outperform votes than Delcath Systems when rated by MarketBeat users. Likewise, 78.99% of users gave Cytosorbents an outperform vote while only 22.33% of users gave Delcath Systems an outperform vote.
Delcath Systems presently has a consensus target price of $20.20, suggesting a potential upside of 208.40%. Cytosorbents has a consensus target price of $2.00, suggesting a potential upside of 125.23%. Given Cytosorbents' stronger consensus rating and higher probable upside, research analysts clearly believe Delcath Systems is more favorable than Cytosorbents.
61.1% of Delcath Systems shares are owned by institutional investors. Comparatively, 32.9% of Cytosorbents shares are owned by institutional investors. 17.9% of Delcath Systems shares are owned by insiders. Comparatively, 6.6% of Cytosorbents shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Delcath Systems has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 0.61, suggesting that its stock price is 39% less volatile than the S&P 500.
Cytosorbents has a net margin of -75.07% compared to Cytosorbents' net margin of -1,080.72%. Delcath Systems' return on equity of -129.89% beat Cytosorbents' return on equity.
Cytosorbents has higher revenue and earnings than Delcath Systems. Delcath Systems is trading at a lower price-to-earnings ratio than Cytosorbents, indicating that it is currently the more affordable of the two stocks.
Summary
Cytosorbents beats Delcath Systems on 10 of the 18 factors compared between the two stocks.
Get Cytosorbents News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTSO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTSO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cytosorbents Competitors List
Related Companies and Tools
